Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. - Archive ouverte HAL
Article Dans Une Revue Transplantation Proceedings Année : 2006

Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation.

A. Al Najjar
  • Fonction : Auteur
I. Etienne
  • Fonction : Auteur
P. Le Pogamp
  • Fonction : Auteur
Yves Le Meur
  • Fonction : Auteur
O. Toupance
  • Fonction : Auteur
C. Mousson
  • Fonction : Auteur
S. Caillard
  • Fonction : Auteur
B. Hurault de Ligny
  • Fonction : Auteur
J. F. Marlière
  • Fonction : Auteur
Y. Lebranchu
  • Fonction : Auteur

Résumé

We compared the influence of induction therapy on 5-year patient and graft survival as well as on renal function in 100 kidney graft recipients at low immunological risk treated with antilymphocyte globulin (n = 50) versus anti-IL-2R monoclonal antibody (n = 50) in a prospective multicenter study. Long-term immunosuppressive treatment included cyclosporine, mycophenolate mofetil, and a short course of steroids in all patients. Five year graft (86% vs 86%) and patient (94% vs 94%) survivals were identical in both study arms. Moreover, neither serum creatinine or proteinuria were significantly different between the two groups. Our results showed that the choice of the induction therapy seemed to not have a major impact on long-term outcomes among renal recipients at low immunological risk.

Domaines

Immunologie

Dates et versions

hal-00453200 , version 1 (04-02-2010)

Identifiants

Citer

A. Al Najjar, I. Etienne, P. Le Pogamp, Franck Bridoux, Yves Le Meur, et al.. Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation.. Transplantation Proceedings, 2006, 38 (7), pp.2298-9. ⟨10.1016/j.transproceed.2006.06.133⟩. ⟨hal-00453200⟩

Altmetric

Partager

More